ClinicalTrials.gg
RecruitingNCT05607498Updated Mar 3, 2025

First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma

A Phase 1 interventional study of EMB07 in Advanced/Metastatic Solid Tumors and Relapse/Refractory Lymphoma, sponsored by EpimAb Biotherapeutics (Suzhou)Co., Ltd.. Recruiting at 10 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-03.

Primary conditionLymphomaRegistry: RecurrenceReclassifiedWhy we changed it
Registry
Recurrence — the first condition term the registry derived for this study.
ClinicalTrials.gg
Lymphoma
Why
  1. Recurrence describes something many studies share rather than a condition a study is about.
  2. The study's listed conditions name Lymphoma.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by EpimAb Biotherapeutics (Suzhou)Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year ago, but the record still lists the study as recruiting.
  • Started Mar 2023; still recruiting 3 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
150
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 276 studies in Lymphoma with a site in China — 103 open to participants now, 119 under way, 10 of them phase 3. Lymphoma · China.

Planned enrollment
41st of 232
150 · median 47
Started
2023
with 28 others
Phase 1
83 of 276
25 open now
Primary completion
2025-10
later than 36 of 118 live
Registered
172nd of 276
by date

Among the 276 studies in Lymphoma with a site in China, this one is the 41st largest by planned enrollment of the 232 interventional ones that give a count, is one of 29 that started in 2023, is one of 83 in phase 1, reaches primary completion later than 36 of the 118 other live ones, and was the 172nd registered.

Lymphoma

3,020 studies on the registry are indexed under Lymphoma; 434 are open to participants now.

Browse Lymphoma studies →

Open to participants now

103 of the 276 studies in Lymphoma with a site in China are open now. Recruiting first, the newest first:

98 more — sign in →

All 103 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 276 studies in Lymphoma with a site in China, or all of them as a file.
02

Study summary

For solid tumors and lymphoma, respectively: This study is to evaluate the safety and tolerability of EMB-07 and to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D). Pharmacokinetics (PK), immunogenicity, and the anti-multiple myeloma activity of EMB-07 will also be assessed.

Read the detailed description

This is a phase I, multicenter, open label, dose escalation, first in human study, designed to assess safety and tolerability, and to identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose for EMB-07 in patient with locally advanced/metastatic solid tumors or relapse/refractory Lymphoma . Pharmacokinetics, pharmacodynamics, immunogenicity and response will also be assessed.

03

Conditions studied

  • Advanced/Metastatic Solid Tumors
  • Relapse/Refractory Lymphoma

Browse trials for

Keywords

  • Phase I
  • Bispecific antibody
  • CD3
  • ROR1
  • EMB07
  • Dose escalation
  • Advanced/Metastatic Solid Tumors
  • Relapse/Refractory Lymphoma
04

In context

Lymphoma Reclassified

3,020 studies on the registry are indexed under Lymphoma; 434 are open to participants now.

This study's planned enrollment of 150 is above the median of 43 across 2,320 interventional studies indexed under Lymphoma.

Browse Lymphoma studies →

Lead sponsor

This is the only study on the registry with EpimAb Biotherapeutics (Suzhou)Co., Ltd. as lead sponsor.

Compared within Lymphoma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Willing and able to provide signed and dated prior to any study-related procedures and willing and able to comply with all study procedures.
  2. Male or female, and aged ≥ 18 years
  3. Treatment group A: Patients with histologically or cytologically locally advanced unresectable or solid tumors limiting to triple-negative breast cancer, lung adenocarcinoma, ovarian cancer, pancreatic cancer, colorectal cancer, gastric cancer, prostate cancer, bladder cancer, and uterus cancer. Treatment group B: Patients with histologically or cytologically relapse/ lymphoma limiting to chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), mantle cell lymphoma (MCL) and diffuse large B cell lymphoma (DLBCL).
  4. Treatment group A: Standard therapies do not exist, or are no longer effective, or are not tolerable or accessible to the patient measurable or evaluable disease per V1.1. Treatment group B: Presence of at least one two-dimensional confirmed by imaging (CT or MRI) (either lymph nodes lesions with any long diameter > 1.5 cm or extranodal lesions with any long diameter > 1.0 cm); for CLL patients whose baseline imaging evaluation determined that no two-dimensional measurable lesions, their peripheral blood monoclonal B lymphocytes should be ≥ 5.0×109/L.
  5. Patients must provide , or a biopsy will be required if archival tumor sample is not available. Archival tumor sample must be taken ≤ 2 years prior to screening, otherwise a fresh tumor biopsy at screening is required.
  6. performance status 0 or 1
  7. Adequate organ function to participate in the trial.
  8. Recovery from adverse events (AEs) related to prior anticancer therapy.

Exclusion criteria

Exclusion Criteria:

  1. Prior treatment with any agent targeting ROR1.
  2. History of Grade 4 immune-related adverse events (irAEs) or irAEs requiring discontinuation of prior therapies.
  3. Patient with primary central nervous system (CNS) or symptomatic . Patients with solid tumors with CNS metastases are eligible if they do not need to receive local radiation treatment at the discretion of investigator or if radiation therapy for CNS metastases is completed ≥ 4 weeks prior to study treatment.
  4. Anticancer therapy or radiation \< 5 half-lives or 4 weeks (whichever is shorter) prior to study treatment.
  5. Abuse on alcohol, cannabis-derived products, or other drugs.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    EMB-07-Patients with solid tumor

    Patients with solid tumor will receive intravenous infusions of EMB-07 weekly (QW). Dose escalation will continue until the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) is reached or all planned doses are administered.

    Drug: EMB07

  • Experimental
    EMB07-Patients with lymphoma

    Patients with lymphoma will receive intravenous infusions of EMB-07 weekly (QW). Dose escalation will continue until the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) is reached or all planned doses are administered.

    Drug: EMB07

Interventions

  • DrugEMB07

    EMB07 is a MAT-Fab bispecific antibody against CD3 and RORI

07

What researchers measure

Primary outcomes

  1. Incidence and severity of adverse events as assessed by CTCAE V5.0.

    Incidence and severity of AE.

    Time frame: Screening up to 30 days after the last dose.

  2. Incidence of serious adverse events (SAE).

    Incidence of SAE.

    Time frame: Screening up to 30 days after the last dose, or beyond 30 days if SAE is confirmed to be treatment related.

  3. Incidence of dose interruptions.

    Incidence of dose interruptions of EMB-07 during treatment as a measure of tolerability.

    Time frame: Screening up to 30 days after the last dose.

  4. Dose intensity.

    Actual amount of drug taken by patients divided by the planned amount.

    Time frame: Screening up to 30 days after the last dose.

  5. The incidence of DLTs during the first cycle of treatment.

    The dose limiting toxicities are based on drug related adverse events and are specifically defined in study protocol.

    Time frame: First infusion to the end of cycle 1. (each cycle is 28 days).

Secondary outcomes

  1. Overall response rate.

    Overall response rate measured by RECIST V1.1, iWCLL-2018, Lugano 2014

    Time frame: From the date of dosing untill the date of first documented progression or date of death from any casue, whichever case first, expected average 6 months.

  2. Area under the serum concentration-time curve (AUC) of EMB-07.

    Blood samples for serum PK analysis will be obtained (AUC).

    Time frame: Through treatment until EOT visit, expected average 6 months.

  3. Maximum serum concentration (Cmax) of EMB-07.

    Blood samples for serum PK analysis will be obtained (Cmax).

    Time frame: Through treatment until EOT visit, expected average 6 months.

  4. Trough concentration (Ctrough) of EMB-07.

    Blood samples for serum PK analysis will be obtained (Ctrough).

    Time frame: Through treatment until EOT visit, expected average 6 months.

  5. Average concentration over a dosing interval (Css, avg) of EMB-07.

    Blood samples for serum PK analysis will be obtained (Css,avg).

    Time frame: Through treatment until EOT visit, expected average 6 months.

  6. Terminal half-life (T1/2) of EMB-07.

    Blood samples for serum PK analysis will be obtained (T1/2).

    Time frame: Through treatment until EOT visit, expected average 6 months.

  7. Systemic clearance (CL) of EMB-07.

    Blood samples for serum PK analysis will be obtained (CL).

    Time frame: Through treatment until EOT visit, expected average 6 months.

  8. Steady state volume of distribution (Vss) of EMB-07.

    Blood samples for serum PK analysis will be obtained (Vss).

    Time frame: Through treatment until EOT visit, expected average 6 months.

  9. Progression free survival (PFS) of EMB-07 as assessed by RECIST 1.1, iWCLL-2018, Lugano 2014

    From the date of dosing until the date of first documented progression or date of death from any cause, whichever came first, expected average 6 months.

    Time frame: Through treatment discontinuation: an average of 6 months

  10. Incidence and titer of anti-drug antibodies stimulated by EMB-07.

    Antibodies to EMB-07 will be assessed to evaluate potential immunogenicity.

    Time frame: Up to End of Treatment Follow Up Period (30 days after the last dose)

08

Study locations

10 of 10 sites recruiting
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Oct 2025, 31 months after the start.

Of 143 industry-sponsored phase 1 interventional studies under Lymphoma, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 60. This study's planned 31 months is below that.

Counting every sponsor, half of 281 studies reached it within 53 months; a quarter within 34 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2022
First posted
Nov 7, 2022
StartActual
Mar 1, 2023
Primary completionEst.
Oct 31, 2025
CompletionEst.
Mar 31, 2026
Last update
Mar 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05607498
Lead sponsor
EpimAb Biotherapeutics (Suzhou)Co., Ltd.
Responsible party
Sponsor
First posted
Nov 7, 2022
Start date
Mar 1, 2023
Primary completion
Oct 31, 2025 (estimated)
Completion
Mar 31, 2026 (estimated)
Last update
Mar 3, 2025

Study contacts

Sai Lou
Contact
slou@epimab.com
+8613758235260
Junqiang He
Contact
jqhe@epimab.com
+8618302157016

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion